Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

FGFR1 (Fibroblast growth factor receptor 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue CGP Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Solid Tumor Kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

CNV+ Breast Cancer NGS Panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

LiquidHALLMARK®

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoScan™ CNV Assay

OncoScan™ CNV Plus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

PredicineCARE™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

StrataNGS™ Test

Tempus xO assay

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue CGP Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Solid Tumor Kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

CNV+ Breast Cancer NGS Panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

LiquidHALLMARK®

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoScan™ CNV Assay

OncoScan™ CNV Plus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

PredicineCARE™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

StrataNGS™ Test

Tempus xO assay

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

›

FGFR1 amplification	Hormone Receptor Positive Breast Cancer	FGFR1 amplification	Hormone Receptor Positive Breast Cancer	letrozole Resistant: B - Late Trials letrozole Resistant : B	letrozole Resistant: B - Late Trials letrozole Resistant : B
FGFR1 mutation	Breast Cancer	FGFR1 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
FGFR1 expression	Ovarian Cancer	FGFR1 expression	Ovarian Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 overexpression	Urothelial Cancer	FGFR1 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR1 expression	Urothelial Cancer	FGFR1 expression	Urothelial Cancer	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2
FGFR1 amplification	Gastric Cancer	FGFR1 amplification	Gastric Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR1 amplification	Bladder Cancer	FGFR1 amplification	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2
FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3